Last updated on October 2016

Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study


Brief description of study

To assess the efficacy of inecalcitol in combination with imatinib in CML patients with molecular residual disease on imatinib monotherapy.

Detailed Study Description

To determine: - Duration of response - Progression free survival - Proportion of responders 2 years after discontinuation of inecalcitol - Duration of response after discontinuation of inecalcitol and imatinib - Bone remodelling effect - Safety of inecalcitol in combination with imatinib - Quality of Life

Clinical Study Identifier: NCT02949570

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Hyacinthe Johnson- Ansah, MD

CHU C te de Nacre
Caen, France
  Connect »